Company Valuation: Tonix Pharmaceuticals

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 177.4 22.42 23.62 61.64 193.6 152.8 - -
Change - -87.36% 5.35% 160.94% 214.02% -21.05% - -
Enterprise Value (EV) 177.4 22.42 23.62 61.64 193.6 152.8 152.8 152.8
Change - -87.36% 5.35% 160.94% 214.02% -21.05% 0% 0%
P/E -1.38x -0.12x -0.06x -0.19x -1.07x -0.91x -1.35x -2.62x
PBR - - - - - - - -
PEG - 0x 0x 0x 0x 0x 0x 0.1x
Capitalization / Revenue - - 3.04x 6.11x 14.8x 2.78x 1.38x 0.84x
EV / Revenue - - 0x 0x 0x 2.78x 1.38x 0.84x
EV / EBITDA - - - - - - - -
EV / EBIT -0x -0x -0x -0x -0x -0.88x -0.94x -1.27x
EV / FCF - - - - - -0.78x -0.75x -0.96x
FCF Yield - - - - - -128% -134% -105%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -166,400 -65,400 -21,920 -176.6 -14.57 -9.792 -6.617 -3.397
Distribution rate - - - - - - - -
Net sales 1 - - 7.768 10.09 13.11 55 110.9 181.4
EBITDA - - - - - - - -
EBIT 1 -92.31 -112.1 -118.4 -136.7 -125.7 -173.3 -161.9 -120.7
Net income 1 -92.29 -116.9 -116.7 -130 -124 -168.7 -164.3 -115.4
Net Debt - - - - - - - -
Reference price 2 228,928.000 7,796.000 1,289.600 32.980 15.620 8.910 8.910 8.910
Nbr of stocks (in thousands) 0.78 2.88 18.3 1,869 12,392 17,151 - -
Announcement Date 3/14/22 3/13/23 4/1/24 3/18/25 3/12/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
32.45x11.78x23.93x0.61% 1,019B
28.48x6.32x17.74x2.09% 617B
33.26x7.78x16.08x2.64% 464B
104.98x5.87x24.89x2.36% 356B
18.81x4.58x11.36x2.9% 333B
19.83x5.17x12.78x3.09% 267B
20.02x4.17x11.86x2.13% 244B
25.46x6.66x11.86x2.5% 218B
-43.78x6.39x24.97x2.27% 179B
Average 26.61x 6.52x 17.28x 2.29% 410.8B
Weighted average by Cap. 31.80x 7.61x 18.61x 1.96%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. TNXP Stock
  4. TNXP Stock
  5. Valuation Tonix Pharmaceuticals